Head and Neck Cancer Treatment Patterns and Outcomes Research Study in France, Germany, and Canada

Bristol-Myers Squibb591 enrolled

Overview

The primary objective of the study is to characterize the medical management of squamous cell carcinoma head and neck (SCCHN) patients diagnosed with recurrent/metastatic (R/M) disease (between 01July2013 and 30 June 2014) in the real-world setting.

Study Type

OBSERVATIONAL

Enrollment

591

Conditions

Head and Neck Cancer

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult patient (18 years old or older) with a confirmed diagnosis or R/M head and neck, may be living or deceased at time of enrollment in the study * Diagnosis of R/M head and neck cancer between 01July2013 and 30June2014 (study index period) Exclusion Criteria: * If female patient, pregnant or lactating between 01July2013 and 30June2014 * Enrolled in cancer treatment-clinical trials since diagnosis of R/M head and neck cancer during the study index period

Outcomes

Primary Outcomes

Best Therapy Response defined as Complete Response (CR), Partial Response (PR), Stable Disease (SD) or Progressive Disease (PD) based on physician's assessment for each therapy regimen